ATE458750T1 - Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren - Google Patents

Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren

Info

Publication number
ATE458750T1
ATE458750T1 AT04809343T AT04809343T ATE458750T1 AT E458750 T1 ATE458750 T1 AT E458750T1 AT 04809343 T AT04809343 T AT 04809343T AT 04809343 T AT04809343 T AT 04809343T AT E458750 T1 ATE458750 T1 AT E458750T1
Authority
AT
Austria
Prior art keywords
coronaviruses
prevention
treatment
control
antiviral agents
Prior art date
Application number
AT04809343T
Other languages
English (en)
Inventor
Abelardo Silva
John Erickson
Original Assignee
Sequoia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequoia Pharmaceuticals Inc filed Critical Sequoia Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE458750T1 publication Critical patent/ATE458750T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04809343T 2003-04-28 2004-04-28 Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren ATE458750T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46578203P 2003-04-28 2003-04-28
US46643203P 2003-04-30 2003-04-30
PCT/US2004/012962 WO2005032453A2 (en) 2003-04-28 2004-04-28 Antiviral agents for the treatment, control and prevention of infections by coronaviruses

Publications (1)

Publication Number Publication Date
ATE458750T1 true ATE458750T1 (de) 2010-03-15

Family

ID=34425768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04809343T ATE458750T1 (de) 2003-04-28 2004-04-28 Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren

Country Status (9)

Country Link
US (2) US7151163B2 (de)
EP (1) EP1620061B1 (de)
JP (1) JP2007526213A (de)
KR (1) KR20060041163A (de)
AT (1) ATE458750T1 (de)
AU (1) AU2004277370A1 (de)
CA (1) CA2524209A1 (de)
DE (1) DE602004025689D1 (de)
WO (1) WO2005032453A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015123315A (ru) 2012-11-25 2017-01-10 Зе Реджентс Оф Зе Юниверсити Оф Калифорния Пептиды, стимулирующие подкожный адипогенез
WO2015184125A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
EP4121025A4 (de) 2020-03-17 2024-03-27 Enzo Biochem, Inc. Verbindungen zur modulierung des sphingosin-signalwegs zur behandlung von coronavirus-infektionen
CA3175831A1 (en) * 2020-04-24 2021-10-28 Matteo Porotto Lipid-peptide fusion inhibitors as sars-cov-2 antivirals
US20230218557A1 (en) * 2020-05-14 2023-07-13 Palani Llc A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections
WO2022026921A1 (en) * 2020-07-30 2022-02-03 Repertoire Immune Medicines, Inc. Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19
JP7302795B2 (ja) * 2020-09-09 2023-07-04 株式会社バイオインテグレンス コロナウイルスの感染防御方法
CN112300290B (zh) * 2020-09-30 2022-04-01 北京康乐卫士生物技术股份有限公司 一种使用乳头瘤病毒类病毒颗粒递呈抗原的新型冠状病毒多肽疫苗
US11479582B2 (en) 2020-10-16 2022-10-25 King Faisal University Anti-SARS-CoV-2 fusion peptides
JP2023551821A (ja) * 2020-11-25 2023-12-13 アヴァイルス，インコーポレイテッド ウイルス感染を治療するための方法及び組成物
US20240307486A1 (en) * 2021-03-30 2024-09-19 Baylor College Of Medicine Methods and compositions for high-potency polypeptide-based protein inhibition
EP4370681A4 (de) * 2021-07-16 2025-11-19 Biocad Joint Stock Co Auf influenzavirus basierendes isoliertes rekombinantes virus
CA3240348C (en) * 2022-02-21 2025-05-13 Youcare Pharmaceutical Group Co., Ltd. Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and use thereof
US20230357325A1 (en) * 2022-05-09 2023-11-09 The Research Foundation for The State of University New york Composition and method to stabilize coronavirus spike glycoproteins in pre-fusion conformation
WO2025147479A1 (en) * 2024-01-04 2025-07-10 Merck Sharp & Dohme Llc Viral fusion inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431194A (en) 1966-10-14 1969-03-04 Exxon Research Engineering Co Process for lowering the pour point of a middle distillate
US4080397A (en) 1976-07-09 1978-03-21 Mobile Oil Corporation Method for upgrading synthetic oils boiling above gasoline boiling material
AU610671B2 (en) 1987-12-18 1991-05-23 Exxon Research And Engineering Company Process for the hydroisomerization of fischer-tropsch wax to produce lubricating oil
US5387348A (en) * 1990-11-09 1995-02-07 Ebara Corporation Method of mixed-bed filtration and demineralization with ion-exchange resins
RU2101324C1 (ru) 1992-08-18 1998-01-10 Шелл Интернэшнл Рисерч Маатсхаппий Б.В. Способ получения углеводородного топлива
US5378348A (en) 1993-07-22 1995-01-03 Exxon Research And Engineering Company Distillate fuel production from Fischer-Tropsch wax
US5888376A (en) 1996-08-23 1999-03-30 Exxon Research And Engineering Co. Conversion of fischer-tropsch light oil to jet fuel by countercurrent processing
FR2799202B1 (fr) 1999-09-30 2002-04-26 Inst Francais Du Petrole Procede de production d'essences a indice d'octane ameliore
CA2391421A1 (en) * 1999-11-12 2001-05-17 Samuel B. Lehrer Compositions and methods for modifying an immune response against tropomyosin
EP1470218B1 (de) * 2001-05-17 2010-07-07 Universiteit Utrecht Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
CA2521856A1 (en) * 2003-04-08 2004-10-21 Coronovative B.V. Severe acute respiratory syndrome (sars) causing coronavirus
US20040229219A1 (en) * 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
CA2441677A1 (en) * 2003-05-09 2004-11-09 Adaltis Inc. Peptides and mixtures thereof for detecting antibodies to severe acute respiratory syndrome-associated coronavirus

Also Published As

Publication number Publication date
US7151163B2 (en) 2006-12-19
KR20060041163A (ko) 2006-05-11
WO2005032453A2 (en) 2005-04-14
US20070185027A1 (en) 2007-08-09
WO2005032453A3 (en) 2007-02-08
EP1620061B1 (de) 2010-02-24
AU2004277370A1 (en) 2005-04-14
JP2007526213A (ja) 2007-09-13
CA2524209A1 (en) 2005-04-14
EP1620061A4 (de) 2007-09-12
DE602004025689D1 (de) 2010-04-08
EP1620061A2 (de) 2006-02-01
US20060258577A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
ATE458750T1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
DK1377314T3 (da) Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
EA200701297A1 (ru) Соединения пиридазинона
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
ATE427116T1 (de) Behandlung von bakteriellen infektionen
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
ATE486634T1 (de) Caspase 3, 8, 9 oder 10 inhibitoren in kombination mit mek inhibitoren zur behandlung von influenza
BRPI0408846A (pt) compostos para o tratamento de infecções por flaviviridae
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
DE60219658D1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
NO20053348L (no) Farmasoytisk sammensetning for behandling av virusangrep.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties